应对奥密克戎疫情爆发的疗法。
Therapeutics to tackle Omicron outbreak.
机构信息
Department of Pharmaceutics & Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad, Gujarat, 380008, India.
Department of Immunology & Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
出版信息
Immunotherapy. 2022 Aug;14(11):833-838. doi: 10.2217/imt-2022-0064. Epub 2022 Jun 8.
Abstract
Tweetable abstract In this commentary, the authors have focused on the mutational impact of the Omicron variant on the current therapeutics to manage #COVID19.
摘要
可发推文的摘要
在这篇评论中，作者重点关注了奥密克戎变异株对目前用于治疗 #COVID19 的药物的突变影响。
相似文献
1
Therapeutics to tackle Omicron outbreak.应对奥密克戎疫情爆发的疗法。
Immunotherapy. 2022 Aug;14(11):833-838. doi: 10.2217/imt-2022-0064. Epub 2022 Jun 8.
2
The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level.SARS-CoV-2 奥密克戎传播控制的快速高效策略：城市级疫情分析。
Infect Dis Poverty. 2022 Nov 24;11(1):114. doi: 10.1186/s40249-022-01043-2.
3
Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates.新冠大流行期间 Delta 和奥密克戎变异株的叠加流行：动态面板数据估计。
JMIR Public Health Surveill. 2022 Jun 3;8(6):e37377. doi: 10.2196/37377.
4
Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022.基于截至 2022 年 3 月 1 日中国所有本地疫情的发病数据，比较不同 COVID-19 株的流行病学特征和传播性。
Front Public Health. 2022 Sep 15;10:949594. doi: 10.3389/fpubh.2022.949594. eCollection 2022.
5
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.奥密克戎 SARS-CoV-2 新变体：全球流行情况以及生物学和临床特征。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. doi: 10.26355/eurrev_202112_27652.
6
Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China.中国衢州 2022 年 3 月至 5 月两次疫情期间 COVID-19 疫苗对 SARS-CoV-2 奥密克戎变异株的有效性。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2163813. doi: 10.1080/21645515.2022.2163813. Epub 2023 Jan 27.
7
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.奥密克戎（B.1.1.529）变异株的中和敏感性：一项横断面研究。
Lancet Infect Dis. 2022 Jun;22(6):813-820. doi: 10.1016/S1473-3099(22)00129-3. Epub 2022 Mar 17.
8
Is Omicron the last SARS-CoV-2 Variant of Concern?奥密克戎是否是最后一个令人关注的 SARS-CoV-2 变体？
Arch Med Res. 2022 Apr;53(3):336-338. doi: 10.1016/j.arcmed.2022.01.001. Epub 2022 Jan 19.
9
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals.在 COVID-19 康复个体中鉴定的与 SARS-CoV-2 的奥密克戎变异株相关的突变和 CD8 T 细胞表位之间最小交叉。
mBio. 2022 Apr 26;13(2):e0361721. doi: 10.1128/mbio.03617-21. Epub 2022 Mar 1.
10
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.免疫功能低下的奥密克戎 BA.1 或 BA.2 感染患者的恢复期血浆治疗。
Influenza Other Respir Viruses. 2024 Mar;18(3):e13272. doi: 10.1111/irv.13272.
引用本文的文献
1
Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics.用于 COVID-19 管理的血液过滤系统：细胞因子风暴治疗的新方法。
Front Immunol. 2023 Apr 21;14:1064459. doi: 10.3389/fimmu.2023.1064459. eCollection 2023.
2
Detection of Circulating SARS-CoV-2 Variants of Concern (VOCs) Using a Multiallelic Spectral Genotyping Assay.使用多等位基因光谱基因分型检测法检测循环中的严重急性呼吸综合征冠状病毒2变异株（VOCs）
Life (Basel). 2023 Jan 21;13(2):304. doi: 10.3390/life13020304.
3
Co-infection associated with SARS-CoV-2 and their management.与严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）相关的合并感染及其管理。
Future Sci OA. 2023 Feb 3;8(9):FSO819. doi: 10.2144/fsoa-2022-0011. eCollection 2022 Oct.
4
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.用于COVID-19治疗的康复期血浆（高免疫球蛋白）：最新情况
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
5
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics.用于 COVID-19 和未来大流行的基于信使核糖核酸的疫苗和疗法。
Vaccines (Basel). 2022 Dec 15;10(12):2150. doi: 10.3390/vaccines10122150.
6
An Impact of COVID-19 on Cancer Care: An Update.2019年冠状病毒病对癌症护理的影响：最新情况
Vaccines (Basel). 2022 Dec 4;10(12):2072. doi: 10.3390/vaccines10122072.
7
SARS-CoV-2: Immunopeptidomics and Other Immunological Studies.严重急性呼吸综合征冠状病毒2：免疫肽组学及其他免疫学研究
Vaccines (Basel). 2022 Nov 21;10(11):1975. doi: 10.3390/vaccines10111975.
8
The Vaccine World of COVID-19: India's Contribution.新冠疫情下的疫苗世界：印度的贡献
Vaccines (Basel). 2022 Nov 17;10(11):1943. doi: 10.3390/vaccines10111943.
9
Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.一氧化氮及其衍生物的鼻腔喷雾剂和吸入疗法用于治疗新冠肺炎。
Curr Pharm Des. 2022;28(46):3658-3670. doi: 10.2174/1381612829666221024124848.
10
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.SARS-CoV-2 疫苗的快速开发：拯救世界的疫苗。
Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022.
本文引用的文献
1
: quest for an eye-opening vaccine breakthrough.寻求具有开创性的疫苗突破。
Expert Rev Vaccines. 2022 Jun;21(6):771-781. doi: 10.1080/14760584.2022.2061461. Epub 2022 Apr 26.
2
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.复制基于病毒载体的 COVID-19 疫苗：疫苗领域的潜在途径。
Viruses. 2022 Apr 6;14(4):759. doi: 10.3390/v14040759.
3
Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?新冠病毒奥密克戎变异株的加强针策略是否足够？
Vaccines (Basel). 2022 Feb 26;10(3):367. doi: 10.3390/vaccines10030367.
4
SARS-CoV-2 variants and vulnerability at the global level.全球层面的 SARS-CoV-2 变体和脆弱性。
J Med Virol. 2022 Jul;94(7):2986-3005. doi: 10.1002/jmv.27717. Epub 2022 Apr 5.
5
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.抗病毒药物对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚型BA.2的疗效
N Engl J Med. 2022 Apr 14;386(15):1475-1477. doi: 10.1056/NEJMc2201933. Epub 2022 Mar 9.
6
Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions.SARS-CoV-2 的奥密克戎变异株（B.1.1.529）：解析基因组、S 糖蛋白和抗体结合区域的突变。
Geroscience. 2022 Apr;44(2):619-637. doi: 10.1007/s11357-022-00532-4. Epub 2022 Mar 8.
7
Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变种（B.1.1.529）：对老年人构成威胁？
Maturitas. 2022 Apr;158:78-81. doi: 10.1016/j.maturitas.2022.01.011. Epub 2022 Jan 29.
8
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.SARS-CoV-2 奥密克戎亚谱系的抗体逃逸特性。
Nature. 2022 Apr;604(7906):553-556. doi: 10.1038/s41586-022-04594-4. Epub 2022 Mar 3.
9
10
A global picture: therapeutic perspectives for COVID-19.全球视角：COVID-19 的治疗展望。
Immunotherapy. 2022 Apr;14(5):351-371. doi: 10.2217/imt-2021-0168. Epub 2022 Feb 21.
Zotero 插件